A research team has developed a new drug that blocks antibodies involved in a disease related to multiple sclerosis.
A study published today in the journal PNAS demonstrates that it may be possible to slow the progression of certain autoimmune diseases using drugs that interfere with the antibodies responsible for these conditions. In mice affected by an autoimmune neurological disease, such a drug reduced symptom severity and restored some functions, including mobility.
“This proof of concept paves the way for a new range of treatments for autoimmune diseases,” says the study’s lead investigator, Luc Vallières , Professor in the Faculty of Medicine at Université Laval and researcher at the CHU de Québec–Université Laval Research Centre.
Read the article: Ulaval Nouvelles
